99065-30-2

Usage

Uses

Used in Pharmaceutical Industry:
D-Cyclohexylalanine hydrochloride is used as a key building block for the synthesis of various pharmaceuticals and biologically active molecules. Its unique cyclic structure and reactivity contribute to the creation of novel compounds with potential therapeutic effects.
Used in Medicinal Chemistry Research:
D-Cyclohexylalanine hydrochloride is utilized as a research compound in medicinal chemistry to explore its antitumor and antiviral properties. Its potential to inhibit the growth of cancer cells and combat viral infections makes it a promising candidate for the development of new therapeutic agents.
Used in Drug Development:
D-Cyclohexylalanine hydrochloride is employed in the development of new drugs with therapeutic applications. Its unique properties allow for the design of innovative pharmaceuticals that can address unmet medical needs and improve patient outcomes.

Upstream product

• 2550-36-9 Cyclohexylmethyl bromide 
• 101426-47-5 2-acetylamino-2-cyclohexylmethylmalonic acid diethyl ester 

Downstream Products

• 557799-48-1 2-Bromo-3-cyclohexyl-propionyl chloride 
• 119860-59-2 N-(Benzyloxycarbonyl)-2(S)-amino-3-cyclohexylpropionic acid 
• 856571-41-0 3-cyclohexyl-2-{2-[(1H-indole-2-carbonyl)amino]benzoylamino}propionic acid ethyl ester 
• 856571-22-7 2-(2-aminobenzoylamino)-3-cyclohexylpropionic acid ethyl ester 

Relevant academic research and scientific papers

Benzoxazinone-containing 3,5-dimethylisoxazole derivatives as BET bromodomain inhibitors for treatment of castration-resistant prostate cancer

The bromodomain and extra-terminal proteins (BET) have emerged as promising therapeutic targets for the treatment of castration-resistant prostate cancer (CRPC). We report the design, synthesis and evaluation of a new series of benzoxazinone-containing 3,5-dimethylisoxazole derivatives as selective BET inhibitors. One of the new compounds, (R)-12 (Y02234), binds to BRD4(1) with a Kd value of 110 nM and blocks bromodomain and acetyl lysine interactions with an IC50 value of 100 nM. It also exhibits selectivity for BET over non-BET bromodomain proteins and demonstrates reasonable anti-proliferation and colony formation inhibition effect in prostate cancer cell lines such as 22Rv1 and C4-2B. The BRD4 inhibitor (R)-12 also significantly suppresses the expression of ERG, Myc and AR target gene PSA at the mRNA level in prostate cancer cells. Treatment with (R)-12 significantly suppresses the tumor growth of prostate cancer (TGI = 70%) in a 22Rv1-derived xenograft model. These data suggest that compound (R)-12 is a promising lead compound for the development of a new class of therapeutics for the treatment of CRPC.

Dynamic Kinetic Resolution of Azlactones by a Chiral N, N-Dimethyl-4-aminopyridine Derivative Containing a 1,1′-Binaphthyl Unit: Importance of Amide Groups

A dynamic kinetic resolution (DKR) of azlactones in the presence of benzoic acid and a binaphthyl-based N,N-4-dimethylaminopyridine (DMAP) derivative 1i having two amide groups at the 3,3′-positions of a binaphthyl unit is developed. The reaction proceeded smoothly with a wide range of azlactones to provide α-amino acid derivatives with good to high enantiomeric ratios (er's). A multigram-scale reaction (2.5 g) for the DKR of azlactone 2d was also demonstrated, and the resulting product was converted to unnatural α-amino acid 6d′.

Anthranilic acid based CCK1 receptor antagonists: Preliminary investigation on their second "touch point"

In this phase of structure-affinity relationship study of VL-0395, a new anthranilic acid based CCK1 selective antagonist, we propose a series of unnatural aminoacidic derivatives. The result of this work is the identification of a new CCK ligand, which possesses an affinity (IC50 = 35 nm) one order of magnitude greater than the lead and, as a general rule, it points out how the hypothesized receptorial pocket which accommodates the Phe residue allows much more structural modification than that interacting with the N-terminal group. Hence, the modification of the C-terminal pharmacophoric group of our lead VL-0395 can not only enhance the affinity of anthranilic acid derivatives but can modulate the selectivity for one CCK receptor subtype or afford mixed antagonists.